Drugs / EP HIV-1090
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00141024 | Jan 2006 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00052182 | Oct 2002 → ? | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00054860 | ? → Sep 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP HIV-1090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00052182 ↗ |
| Modality | Vaccine | “The DNA-based vaccine in this study is designed to boost the immune system's responses against many HIV-1 proteins.” NCT00052182 ↗ |
| Route | Intramuscular | “The injections will be delivered intramuscularly into the deltoid muscle.” NCT00052182 ↗ |